$1.88
+0.27%
N/A+$0.01
헬스케어
생명공학
NASDAQ
활발히 거래 중
Lantern Pharma Inc.는 인공지능, 머신러닝, 포괄적인 유전체 데이터 분석의 전략적 적용을 통해 약물 개발을 혁신하는 데 전념하는 임상 단계 생명공학 기업입니다. 이들의 ...
Lantern Pharma Inc.는 인공지능, 머신러닝, 포괄적인 유전체 데이터 분석의 전략적 적용을 통해 약물 개발을 혁신하는 데 전념하는 임상 단계 생명공학 기업입니다. 이들의 ...
LP-100 is a clinical-stage drug candidate currently undergoing Phase II clinical trials. It is designed to target specific patient populations identified through Lantern Pharma's AI-driven biomarker analysis to improve efficacy in treating prostate cancer.
가격대: N/A (Clinical-stage therapeutic)
페인 포인트: Low success rates of oncology drugs in broad, non-stratified patient populations.
솔루션: Targeted therapy for patients with specific genomic profiles, increasing the likelihood of clinical success.
대상 사용자: Patients with metastatic, castration-resistant prostate cancer identified as responders through biomarker screening.
LP-300 is an investigational drug aimed at improving treatment outcomes for never-smokers with relapsed advanced primary adenocarcinoma of the lung. It is currently the subject of the HARMONIC Phase 2 clinical trial.
가격대: N/A (Clinical-stage therapeutic)
페인 포인트: Limited effective treatment options for lung cancer patients who have never smoked.
솔루션: Evidence-based targeted intervention designed to deepen progression-free survival.
대상 사용자: Never-smokers diagnosed with relapsed advanced primary adenocarcinoma of the lung.
LP-184 is a potent alkylating agent engineered to inflict DNA damage upon cancer cells that overexpress specific biomarkers or have mutations in their DNA repair pathways.
가격대: N/A (Clinical-stage therapeutic)
페인 포인트: Resistance of specific cancers to standard chemotherapy.
솔루션: Targeted DNA damage induction specifically in cells with repair pathway deficiencies.
대상 사용자: Cancer patients whose tumors exhibit specific DNA repair mutations or biomarker expressions.
LP-284 is in preclinical development, utilizing similar synthetically lethal principles as LP-184, targeting cancers with specific genetic vulnerabilities related to DNA damage repair.
가격대: N/A (Clinical-stage therapeutic)
페인 포인트: Lack of targeted therapies for cancers with specific DNA repair pathway mutations.
솔루션: Precision targeting of cancer cells using AI-derived insights.
대상 사용자: Patients with cancers exhibiting high sensitivity to synthetically lethal therapeutic intervention.
The RADR platform integrates over 200 billion oncology-focused data points and 200+ machine learning algorithms to identify optimal therapeutic candidates, patient subpopulations, and drug combinations, significantly reducing development timelines.
가격대: N/A (Proprietary internal platform/partnership model)
페인 포인트: High cost and high failure rates in traditional oncology drug development.
솔루션: Data-driven hypothesis testing, patient stratification, and shortened R&D timelines.
대상 사용자: Internal Lantern Pharma R&D and external biopharma partners.
withZeta.ai is a natural language-based AI platform that unifies clinical, molecular, and therapeutic literature to reveal hidden insights and therapeutic opportunities in rare and understudied cancers.
가격대: N/A (Proprietary technology)
페인 포인트: Information overload and silos in clinical and molecular research data.
솔루션: Automated, evidence-grounded insights that accelerate the discovery process for rare diseases.
대상 사용자: Oncology researchers and pharmaceutical development teams.
PredictBBB.ai is part of Lantern's technological suite aimed at predicting whether drug molecules can successfully cross the blood-brain barrier, which is critical for treating brain cancers and central nervous system metastases.
가격대: N/A (Proprietary technology)
페인 포인트: Difficulty in identifying effective drugs capable of penetrating the blood-brain barrier.
솔루션: Computational prediction of drug efficacy in CNS-related indications, reducing experimental trial-and-error.
대상 사용자: Oncology drug discovery scientists and CNS therapeutic development teams.